Informations générales (source: ClinicalTrials.gov)
BeAT1D: Benign Autoimmunity and Type 1 Diabetes (BeAT1D)
Observational
Institut National de la Santé Et de la Recherche Médicale, France (Voir sur ClinicalTrials)
octobre 2022
décembre 2027
29 juin 2024
National multi-center non-interventional case-control cohort study with collection of
biological samples to characterize the autoimmune T and B lymphocytes involved in the
development of type 1 diabetes.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | CAMPINOS Catherine | 14/02/2025 09:03:13 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Avicenne | Emmanuel Cosson, MD PhD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Bicêtre | Cécile Petit-Bibal, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Bichat | Ronan Roussel, MD PhD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Cochin | Pierre-Philippe Massault, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Europeen Georges Pompidou | Alina Radu, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Jean Verdier | Nadine Lucidarme, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Louis Mourier | Stéphanie Gréteau-Hamoumou, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Bruno Fève, MD PhD | Contact (sur clinicalTrials) | |||
| CENTRE HOSPITALIER SUD FRANCILIEN | Alfred Penfornis, MD PhD | Contact (sur clinicalTrials) | |||
| CH DE VERSAILLES SITE ANDRE MIGNOT | Catherine Ajzenman, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| APHP Hôpital Lariboisière - 75010 - Paris - Ile-de-France - France | Jean-François Gautier, MD PhD | Contact (sur clinicalTrials) | |||
| APHP Hôpital Pitié-Salpêtrière - Service de Chirurgie - 75013 - Paris - Ile-de-France - France | Sébastien Gaujoux, MD PhD | Contact (sur clinicalTrials) | |||
| APHP Hôpital R. Debré - 75019 - Paris - Ile-de-France - France | Elise Bismuth, MD | Contact (sur clinicalTrials) | |||
| Hôpital Pitié-Salpêtrière - Service de Diabétologie - 75013 - Paris - Ile-de-France - France | Chloé Amouyal, MD PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin
therapy started within 6 months from clinical onset; and/or the presence of at least
one anti-islet auto-antibody.
2. Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g.
type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or
other autoimmune endocrinopathies, isolated or multiple.
3. No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor,
infectious or immune pathologies, or other conditions related to autoimmune or
metabolic alterations that may bias the variables under study.
4. Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic
lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of
an underlying condition.
1. Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin
therapy started within 6 months from clinical onset; and/or the presence of at least
one anti-islet auto-antibody.
2. Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g.
type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and/or
other autoimmune endocrinopathies, isolated or multiple.
3. No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor,
infectious or immune pathologies, or other conditions related to autoimmune or
metabolic alterations that may bias the variables under study.
4. Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic
lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of
an underlying condition.
For all participants: ongoing pregnancy; known HIV/HCV infection; absence of social
security coverage; placement under judicial protection; absence of signature of the
informed study consent.